Litchfield Hills Research Rates Predictive Oncology a Buy on Recent Analyst Report
February 02 2021 - 8:30AM
Predictive Oncology (NASDAQ: POAI), a
knowledge-driven company focused on applying artificial
intelligence (“AI”) to personalized medicine and drug discovery,
announced today that equity research firm, Litchfield Hills
Research LLC, released its first analyst coverage report on
(Nasdaq: POAI), rating the Company a "Buy" under its three-tiered
(buy-hold-sell) rating system.
Litchfield Hills Research adheres to FINRA
standards for quality and objectivity. The Litchfield Hills
Research Department certifies its report is compliant with FINRA
research rules 2241, 3110, the Litchfield is registered with FINRA,
and the report has been reviewed by a Supervisory Senior Analyst.
Litchfield’s price target, financial models, peer comparisons, and
investment thesis are developed without input from management of
the company, and they performed their own due diligence.The
research report is MiFID II compliant and is classified as minor
non-monetary benefit under MiFID II. It is accessible on Bloomberg,
FactSet, NASDAQ, NYSE Connect, S&P Cap IQ, Thomson Reuters
(Refinitiv) and 12 other platforms around the globe. It will be
posted to the research firm’s
website http://www.hillsresearch.com/current-research/.
About Predictive Oncology
Inc.
Predictive Oncology (NASDAQ: POAI) operates
through three segments (Skyline, Helomics and Soluble Biotech),
which contain four subsidiaries: Helomics, TumorGenesis, Skyline
Medical and Soluble Biotech.
Helomics applies artificial intelligence to its
rich data gathered from patient tumors to both personalize cancer
therapies for patients and drive the development of new targeted
therapies in collaborations with pharmaceutical companies.
TumorGenesis Inc. specializes in media that help cancer cells grow
and retain their DNA/RNA and proteomic signatures, providing
researchers with a tool to expand and study cancer cell types found
in tumors of the blood and organ systems of all mammals, including
humans. Skyline Medical markets its patented and FDA cleared
STREAMWAY System, which automates the collection, measurement, and
disposal of waste fluid, including blood, irrigation fluid and
others, within a medical facility, through both domestic and
international divisions. Soluble Biotech is a provider of soluble
and stable formulations for proteins including vaccines,
antibodies, large and small proteins, and protein complexes.
Forward-Looking Statements
Certain matters discussed in this release contain
forward-looking statements. These forward-looking statements
reflect our current expectations and projections about future
events and are subject to substantial risks, uncertainties and
assumptions about our operations and the investments we make. All
statements, other than statements of historical facts, included in
this press release regarding our strategy, future operations,
future financial position, future revenue and financial
performance, projected costs, prospects, plans and objectives of
management are forward-looking statements. The words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,”
“target” and similar expressions are intended to identify forward-
looking statements, although not all forward-looking statements
contain these identifying words. Our actual future performance may
materially differ from that contemplated by the forward-looking
statements as a result of a variety of factors including, among
other things, factors discussed under the heading “Risk Factors” in
our filings with the SEC. Except as expressly required by law, the
Company disclaims any intent or obligation to update these
forward-looking statements.
Investor Relations Contact:
Landon Capital Keith Pinder (404)
995-6671kpinder@landoncapital.net
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024